Trial	Characteristic	Endpoint reported in publication	Endpoint not reported in publication	Time of measurementa
Ferguson 2001	Review's primary outcomes
	All‐cause mortality	‐	x	‐
	Macrovascular complications	‐	x	‐
	Microvascular complications	‐	x	‐
	Severe hypoglycaemic episodes (P)	x	‐	4, 8, 12, 16, 20, 24 weeks
	Review's secondary outcomes
	Glycaemic control (HbA1c) (O)	x	‐	0, 24 weeks
	Adverse events (O)	x	‐	24 weeks
	Health related quality of life (O)	xc	‐	0, 24 weeks
	Costs	‐	x	‐
	Other than review's primary/secondary outcomes reported in publication (classification: P/S/O)b
	Participant satisfaction (O), pre‐ and post‐prandial blood glucose (O)
	Subgroups reported in publication
	‐
Home 2000	Review's primary outcomes
	All‐cause mortality (O)	x	‐	6 months
	Macrovascular complications	‐	x	‐
	Microvascular complications	‐	x	‐
	Severe hypoglycaemic episodes (O)	x	‐	6 months
	Review's secondary outcomes
	Glycaemic control (HbA1c) (P)	x	‐	0, 2 weeks, 1, 2, 3, 4, 5, 6 months
	Adverse events (O)	x	‐	6 months
	Health‐related quality of life (O)	xd	‐	0, 3, 6 months
	Costs	‐	x	‐
	Other than review's primary/secondary outcomes reported in publication (classification: P/S/O)b
	Treatment satisfaction (O)
	Subgroups reported in publication
	‐
Iwamoto 2001	Review's primary outcomes
	All‐cause mortality	‐	x	‐
	Macrovascular complications	‐	x	‐
	Microvascular complications	‐	x	‐
	Severe hypoglycaemic episodes	‐	x	‐
	Review's secondary outcomes
	Glycaemic control (HbA1c) (P)	x	‐	0, 4, 8, 16, 20, 24 weeks
	Adverse events (O)	x	‐	0, 4, 8, 16, 20, 24 weeks
	Health‐related quality of life	‐	x	‐
	Costs	‐	x	‐
	Other than review's primary/secondary outcomes reported in publication (classification: P/S/O)b
	Weight (O), insulin antibodies (O), insulin dose (O), blood pressure (O), fasting and post‐prandial blood glucose (O)
	Subgroups reported in publication
	‐
Provenzano 2001	Review's primary outcomes
	All‐cause mortality (O)	x	‐	‐
	Macrovascular complications	‐	x	‐
	Microvascular complications	‐	x	‐
	Severe hypoglycaemic episodes	‐	x	‐
	Review's secondary outcomes
	Glycaemic control (HbA1c) (O)	x	‐	‐2, 0, 6, 12, 18, 24 weeks
	Adverse events (O)	x	‐	every 15 days
	Health related quality of life	‐	x	‐
	Costs	‐	x	‐
	Other than review's primary/secondary outcomes reported in publication (classification: P/S/O)b
	‐
	Subgroups reported in publication
	‐
Raskin 2000	Review'sprimary outcomes
	All‐cause mortality	‐	x	‐
	Macrovascular complications	‐	x	‐
	Microvascular complications	‐	x	‐
	Severe hypoglycaemic episodes (O)	x	‐	12 months
	Review'ssecondary outcomes
	Glycaemic control (HbA1c) (P)	x	‐	0, 12 months
	Adverse events (O)	x	‐	12 months
	Health‐related quality of life	‐	x	‐
	Costs	‐	x	‐
	Other than review's primary/secondary outcomes reported in publication (classification: P/S/O)b
	Post‐prandial blood glucose (O)
	Subgroups reported in publication
	‐
Recasens 2003	Review'sprimary outcomes
	All‐cause mortality	‐	x	‐
	Macrovascular complications	‐	x	‐
	Microvascular complications	‐	x	‐
	Severe hypoglycaemic episodes (O)	x	‐	12 months
	Review'ssecondary outcomes
	Glycaemic control (HbA1c) (O)	x	‐	0, 12 months
	Adverse events (O)	x	‐	12 months
	Health‐related quality of life	‐	x	‐
	Costs	‐	x	‐
	Other than review's primary/secondary outcomes reported in publication (classification: P/S/O)b
	‐
	Subgroups reported in publication
	‐
Z011 2007	Review'sprimary outcomes
	All‐cause mortality (O)	x	‐	12 months
	Macrovascular complications	‐	x	‐
	Microvascular complications	‐	x	‐
	Severe hypoglycaemic episodes (O)	x	‐	12 months
	Review'ssecondary outcomes
	Glycaemic control (HbA1c) (O)	x	‐	0, 3, 6, 12 months
	Adverse events (O)	x	‐	12 months
	Health‐related quality of life	‐	x	‐
	Costs	‐	x	‐
	Other than review's primary/secondary outcomes reported in publication (classification: P/S/O)b
	‐
	Subgroups reported in publication
	‐
Z013 2007	Review'sprimary outcomes
	All‐cause mortality (O)	x	‐	12 months
	Macrovascular complications	‐	x	‐
	Microvascular complications	‐	x	‐
	Severe hypoglycaemic episodes (O)	x	‐	12 months
	Review'ssecondary outcomes
	Glycaemic control (HbA1c) (O)	x	‐	0, 3, 6, 12 months
	Adverse events (O)	x	‐	12 months
	Health‐related quality of life	‐	x	‐
	Costs	‐	x	‐
	Other than review's primary/secondary outcomes reported in publication (classification: P/S/O)b
	‐
	Subgroups reported in publication
	‐
Z015 2007	Review'sprimary outcomes
	All‐cause mortality (O)	x	‐	12 months
	Macrovascular complications	‐	x	‐
	Microvascular complications	‐	x	‐
	Severe hypoglycaemic episodes (O)	x	‐	12 months
	Review'ssecondary outcomes
	Glycaemic control (HbA1c) (O)	x	‐	0, 3, 6, 12 months
	Adverse events (O)	x	‐	12 months
	Health‐related quality of life	‐	x	‐
	Costs	‐	x	‐
	Other than review's primary/secondary outcomes reported in publication (classification: P/S/O)b
	‐
	Subgroups reported in publication
	‐
aUnderlined data denote times of measurement for primary and secondary review outcomes, if measured and reported in the results section of the publication (other times represent planned but not reported points in time) b(P) Primary or (S) secondary endpoint(s) refer to verbatim statements in the publication, (O) other endpoints relate to outcomes that were not specified as 'primary' or 'secondary' outcomes in the publication cThe publication reports on only one questionnaire, while the trial documents described two different questionnaires dOnly reported for the German subpopulation (Bott 2003) HbA1c: glycosylated haemoglobin A1c; O: other endpoint; P: primary endpoint; S: secondary endpoint